Ironwood Pharmaceuticals (IRWD) news
Recent news
Ironwood Pharmaceuticals outlook FY revenue USD 460-485 million
AInvest Wire · Aug 6, 2026Ironwood Pharmaceuticals raises 2026 year finl guidance
AInvest Wire · Aug 6, 2026Ironwood Pharmaceuticals Q2 basic EPS USD 0.31
Ironwood Pharmaceuticals (NASDAQ: IRWD) reported Q2 2026 earnings results on August 6, with basic earnings per share (EPS) of $0.31, slightly below the $0.32 per share projected . The company generated revenue of $114.8 million , aligning closely with expectations. This represents an increase from…
AInvest Wire · Aug 6, 2026Ironwood 2Q adj EPS 31c, est. 34c
Ironwood Pharmaceuticals (NASDAQ: IRWD) reported adjusted earnings per share (EPS) of $0.31 for the second quarter of 2025, slightly below the estimated $0.34 . The company’s GAAP revenue for the quarter was $85.2 million, surpassing the projected $60.8 million . Despite the revenue beat, the…
AInvest Wire · Aug 6, 2026Ironwood 2Q revenue $113.0M, estimate $117.5M
AInvest Wire · Aug 6, 2026Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.